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Retroviruses encode a protease which cleaves the 
viral Gag and Gag/Pol protein precursors into mature 
products. To understand the target sequence specificity 
of the viral protease, the amino acid sequences from 
46 known processing sites from 10 diverse retrovi- 
ruses were compared. Sequence preference was evi- 
dent in positions P4 through P3‘ when compared to 
flanking sequences. Approximately 80% of all  cleavage 
site sequences could be grouped into two  classes based 
on the sequence composition flanking the scissile bond. 
The sequences at the amino-terminal cleavage  site of 
the major capsid protein of Gag is always a  member  of 
one of the two classes while the carboxyl-terminal 
cleavage  site is of the other class, suggesting a biolog- 
ical role for the two classes. Known processing site 
sequences proved useful in a motif searching strategy 
to identify processing sites in retroviral protein se- 
quences, particularly in Gag. In all known cleavage 
sites, the P1 amino acid is hydrophobic  and  unbranched 
at the j3-carbon. The sequence requirements of the P1 
position were tested by site-directed mutagenesis of 
the P1 Phe codon in an HIV-1 Pol cleavage  site. Mu- 
tations were tested for protease-mediated cleavage of 
the Pol precursor expressed in Escherichia  coli. 
Several retroviral  proteins  undergo  proteolytic processing 
by the  viral  protease  (PR)’  during virion  assembly and  mat- 
uration. The Gag and Gag/Pol polyprotein precursors are 
processed by the viral PR to generate the viral structural 
proteins (encoded in the gag gene) and enzymes (encoded 
within  thepol gene) (reviewed in Refs. 1,2).  In  all  retroviruses, 
proteolytic processing of the Gag polyprotein  generates  the 
matrix  protein,  the  capsid  protein,  and  the nucleocapsid pro- 
tein.  Processing of the  Gag/Pol  precursor p oduces the reverse 
transcriptase, RNase H, and integrase. Depending on the 
retrovirus,  the P R  is encoded either  in gag, pol, or in a small 
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open  reading  frame (pro) located  between gag and pol. Prote- 
olytic  processing of the  precursors by the  retroviral  PR is an 
obligatory step  in  the  formation of mature, infectious  virions 
(3-8). HIV-1 mutants containing an inactive PR produce 
defective, noninfectious virions lacking the condensed core 
characteristic of mature  virions  (5, 9, 10). 
Several  lines of evidence indicate  retroviral  proteases  are 
members of the  aspartic  proteinase family of proteases. How- 
ever, the  viral  proteases differ  from  cellular aspartic  protein- 
ases in that  they  are  smaller  and  function  as  dimer (11-19). 
Substrate binding occurs within a cleft that is formed by 
symmetrical  association of two P R  monomers. Each monomer 
contains a  flap that folds over the cleft that may contribute 
to  substrate recognition and  binding  through  interaction with 
the  substrate (20-22). 
The mechanism of processing site recognition  in the  pre- 
cursor proteins by the viral protease is poorly understood. 
The  PR is highly specific in  site selection;  only a few sites  are 
cleaved in  either  the Gag or Gag/Pol  precursor  proteins.  The 
cleavages are conservative in that only the scissile peptide 
bond  is hydrolyzed at  each cleavage site.  Despite  the specific- 
ity of site selection,  recognition  sequences  for the  retroviral 
PR are diverse in amino acid composition (1). Structural 
studies of the  HIV-1  PR  and  substrate  analogs uggests 6 to 
7 residues of the  substrate reside in  the  binding cleft (20, 22, 
23). Studies with peptide substrates suggest the minimum 
substrate  length for retroviral  proteases  is small (24, 25). The 
minimum  substrate  length for the  HIV-1  PR  corresponds  to 
positions  P4  through  P3’  flanking  the scissile bond (26-28) 
(P1 is  the  first  amino acid upstream of the scissile bond, P1’ 
is  the  first  amino acid downstream). 
To understand cleavage site specificity, we analyzed 46 
known retroviral P R  cleavage site sequences  from 10  different 
retroviruses  to  characterize  amino acid  preferences in  proc- 
essing  site sequences.  Amino  acid  preference  was evident from 
position P4 through P3’ flanking the scissile bond. Most 
significantly, the  identity of the  amino acid in  the P1’ position 
correlated  with two distinctive  patterns  in  the composition of 
the  flanking  amino acid  sequence.  Approximately 80% of the 
processing sites examined could be classified as  one of the 
two types of sites.  The  type of processing site was conserved 
a t  certain locations in the retroviral genomes, suggesting a 
biological role for the two classes of sites. In addition, the 
sequence requirement of the P1 amino acid, which is always 
hydrophobic and  unbranched  at  the  @-carbon, was examined 
experimentally by mutagenesis of a Phe/Pro-processing  site 
located at  the  amino  terminus of the  HIV-1  PR. Analysis of 
the effects of the  mutations  on processing of the  Pol polypro- 
tein was accomplished by an expression system  in which Pol 
is processed to  completion in Escherichia coli. 
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MATERIALS AND METHODS 
Searches of Retrouiral Protein  Sequences-The sequence analysis 
programs WEIGHTS and ANALYSEP (29, 30) were used in the 
search for cleavage site sequences. Putative  amino acid  sequences of 
the gag,  pol, and pro open  reading  frames were obtained by translation 
of the genomic sequence of virus nucleotide  sequences  deposited in 
the EMBL/GenBank/DDBJ nucleotide sequences databases. The 
GenBank asscession numbers of the  retroviruses used are  as follows: 
BLV, M10987; EIAV, M16575, M11337, K03334, M14855; HIV-1 
(HXBZD), K03455; HTLV-11, A03944, A03962, A03954; MPMV, 
M12349; MMTV, M15122, Mo-MuLV, 502255,502256,502257;  RSV, 
502342, 502021, 502343; SIV,,,; M16403, Y00277. The  citations for 
viral  sequences can be found in  the  database sequence files. 
Plasmid Constructions-The phagemid used for mutagenesis, se- 
quencing, and expression of the  HIV-1 pol gene was pART2.  pART2 
contains  the pol gene  from HIV-1 isolate HXB2D  (31)  inserted  into 
the vector  pIBI20 (International Biotechnologies) (32, 33).  Features 
of pART2 include the pol gene under  transcriptional  control of the 
lac promoter, and an f l  phage origin of replication to allow the 
production of single-stranded  DNA for  use in  site-directed  random 
mutagenesis and DNA sequencing (32,  34). 
Design  and  Synthesis of Mutagenic D N A  Oligonucleotides  and  the 
Production  and  Screening of Mutations  in  the HIV-1 pol  Gene-To 
produce  random mutations  in  the codon for the P1 amino  acid of the 
Pol cleavage site located at  the  amino  terminus of the  PR domain 
upstream of reverse transcriptase, a 25-base DNA oligonucleotide 
was  synthesized complementary  to  single-stranded  pART2  except for 
the  three  positions of the  target codon  where all four  nucleotides were 
inserted  with equal  frequency. Single-stranded  uracil-substituted 
pART2 for use in  mutagenesis was prepared by passaging the vector 
once through E. coli strain  CJ236 (dut-   ung-)  (35). In vitro mutagen- 
esis reactions  and  preparation of pART2  libraries  containing  muta- 
tions were performed as previously  described  (32,  33,  35). Individual 
plasmid clones of the  library were rescued as  single-stranded DNA 
by infection with M13K07(b) helper phage (34). Mutations in the 
codon for the  P1 amino acid were identified by DNA  sequence analysis 
using the dideoxy-chain termination  method  (36). 
Induction of Expression of the  Pol  Gene i n   E .  coli-E. coli strain 
JMlOl containing either pART2 or pART2 with mutations were 
grown overnight in modified M9  medium (no glucose, 0.4% casamino 
acids, 100 pg/ml  ampicillin, 0.001% thiamine)  (37).  Expression of the 
pol gene from the lac promoter was induced by the addition of 
isopropyl-6-o-thioglactopyranoside to a final  concentration of 5 mM. 
After 90 min, the bacteria were pelleted by centrifugation, resus- 
pended in 1/10  volume of sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis loading buffer (0.25 M Tris-C1, pH 6.8, 4% sodium 
dodecyl sulfate, 20% glycerol, 10% 6-mercaptoethanol, 0.05% brom- 
phenol  blue),  and lysed  by heating to  100 “C for 3 min. 
Phenotypic  Screening  and  Western  Blot  Analysis-In the  Western 
blot analysis of Pol processing, 10 pl of sample was subjected to  
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (38) and 
transblotted a t  70 V  (300 mAmp) for 1 h onto nitrocellulose 
(Schleicher & Schuell BA 85) in buffer containing 25 mM Tris-C1, 
pH 8.3, 192 mM glycine, and 20% (v/v)  methanol.  Blots were washed 
in  phosphate-buffered  saline pH 7.2 (PBS) twice for 5 min, blocked 
for 1 h in 3% gelatin in PBS, and exposed to 10 pl of anti-RT 
monoclonal (Du Pont) or anti-PR polyclonal antibody in 10 ml of 
I’BS + 0.1%  Tween 20 (PBS-Tw) for  2  h a t  room temperature.  Blots 
were washed three  times for 5 min  in  PBS-Tw  and  reacted  with a 
1:2000 dilution of either goat anti-rabbit  or  goat  anti-mouse  antibody 
conjugated  with alkaline  phosphatase  in 10 ml of PBS-Tw for 1 h at 
room temperature  (Promega Biotechnologies). The blots were then 
washed twice for 5 min in PBS-Tw, 5 min in Tris-buffered saline, 
and 5  min in  carbonate buffer, pH 9.8 (0.1 M NaHCOs, 1 mM MgCl,). 
Color was developed using 5-bromo-4-chloro-3-indolyl phosphate- 
toluidine  salt  and  p-nitro-blue  tetrazolium  as  substrates for alkaline 
phosphatase according to  the  instructions of the  manufacturer  (Bio- 
Had). 
RESULTS 
Two  Sequence  Families  Correlate  with the PI’ Amino  Acid 
Sequence-To identify amino acid  sequence determinants  in 
the  substrate  that define PR specificity,  a database  containing 
46 different  processing site sequences  from 10 highly divergent 
retroviruses was compiled (Table  I).  The cleavage sites were 
selected discriminately by choosing  only sites proven by 
amino-terminal  sequencing of the  protein  products. Several 
types of analyses were applied to  the  data base of sequences. 
First,  substrate  positions P10 through P10’ were analyzed to 
determine  amino acid  variability, the composition of amino 
acids, and the average hydrophobicity of the amino acids 
located in each  position (Table 11). Less sequence  variability 
was evident  in  positions P4 through P3‘. The four positions 
closest to  the scissile bond (P2 through P2’) were the most 
restricted  in  amino acid  composition  (Fig. 1A). The exception 
was the P3 position, which was as  variable  as  positions  farther 
away from the scissile bond. The  amino acid  composition in 
positions P10 through P10’ was also  analyzed  for hydropath- 
icity (39) (Fig. 1B). Amino acids in substrate positions P2 
through P3’ were increased  in  hydropathicity relative to  the 
flanking sequences. Hydropathicity  and sequence  variability 
data, when taken together, suggested substrate sequences 
important for interaction  with  retroviral  proteases generally 
extend  from  positions P4 through P3’. These  positions  cor- 
respond to the minimum substrate length of seven amino 
acids (P4 through P3’) required for cleavage by the  HIV-1 
PR  (26, 27, 28). 
The PR cleavage site sequences were also  analyzed to 
ascertain if the  presence of a certain  amino acid at  any  one 
position predisposes the  appearance of any  particular  amino 
acid at another position. This  analysis was  accomplished  by 
correlating amino acids that appear frequently at specific 
positions between P5 and P5’ with the  frequent  appearance 
of specific amino  acids at  other  positions.  The  analysis  indi- 
cated  most processing site sequences could be grouped into 
two  classes  based on two patterns of sequence  preference that 
were evident from positions P4 through P3’. Differences in 
flanking  amino acid  composition in  the two classes correlated 
with the amino acid in the P1’ position of the substrate. 
Based  on  this  analysis, we have designated  the two  classes of 
cleavage sites as type 1 and  type 2 sites. Type 1 sites have 
Pro in  the P1’ position (Table 111), while type 2 sites have 
either  Leu, Ala or Val in  the P1’ position  (Table IV).  Differ- 
ences  in  amino acid preference  in  the two types of sites were 
quite obvious. For example, type 1 sites  frequently have Phe 
or Tyr  in  the P1 position while type 2 sites favor Leu over 
Phe or Tyr.  In  contrast  to  the differences in sequence pref- 
erence between the two types of site, there were several 
sequence preferences that were apparently shared by both 
classes of sites. For example, amino acids with side chains 
branched at  the  P-carbon  (Ile, Val) were excluded from the 
P1 position of all the processing site sequences (Table 11). 
The  patterns of differences and  similarities  in  the  positions 
flanking  the P1’ amino acid in  the two types of PR cleavage 
sites  can be summarized  as follows: P4, small  amino acids in 
both types of sites (Pro, Ser, Thr, Gly, Ala); P3, generally 
uncharged  with  Gln  seen  in some type 1 sites  and Arg/Lys 
seen  in  some  type 2 sites; P2, aliphatic for both  types of sites 
but  with Asn  occasionally seen  and Val largely excluded  from 
type 1 sites; PI, Tyr, Phe, Leu predominate in type 1 sites 
while Leu predominates  in  type 2 sites; Pl’, Pro (type 1) and 
the amino acids Ala, Leu, and Val (type 2) define the two 
types of sites; P2’, aliphatic in both types (Ile is excluded 
from  type 2 sites); P3’, aliphatic  in  both  types (Ala is favored 
in  type 2 sites). 
While  approximately 80% of processing site sequences were 
either type 1 or type 2 sites by the composition of the P1 
amino acid,  some PR cleavage site sequences contained  amino 
acids  other  than Pro, Leu, Val, or Ala at  the P1’ position. 
Nine  such  sites  are  listed  in  Table I. These  sites  as a  group 
shared the general features of type 2 sites, although polar 
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TABLE I 
Tabulation of known protease cleavage sites 
The abbreviations used are: MA, matrix protein; CA, capsid protein; NC, nucleocapsid protein; RT, reverse 
transcriptase;  IN,  integrase;  BLV,  bovine  leukemia  virus;  EIAV;  equine  infectious  anemia  virus;  HTLV,  human T- 
cell lymphotropic virus; MMTV, mouse mammary tumor virus; MPMV, Mason-Pfizer monkey virus; MuLV, 
Moloney  murine  leukemia  virus;  RSV,  Rous  sarcoma  virus  (Prague  strain  subgroup  C);  SIVmac,  simian  immuno- 
deficiencv  virus  (macaaue). 
Virus Protease cleavaee site seauence Refs. 
BLV 
MA/CA P P P Y D P P A I L I P I I S E G N R N R  53 
CA/NC A P K V K Q P A I L / V H T P G P K M P G  54 
x/PR P L S E A E L E C L / L S I P L A R S R P  55 











































K K Q S E P S E E Y / P I M I D G A G N R  
I G T T K Q K M M L I L A K A L Q T G L A  
Q K M M L L A K A L / Q T G L A G P F K G  
A Q G R P Q K Q T F I P I Q Q K S Q H N K  
Y V E P T A P Q V L / P V M H P H G A P P  
W T P K D K T K V L / V V Q P K K P P P N  
Y V E P T T T Q C F / P I L H P P G A P S  
W T P K D K T K V L / V V Q P R R P P P T  
G H S N Q V S Q N Y / P I V Q N I Q G Q M  
G G P G H K A R V L / A E A M S Q V T N S  
S Q V T N S A T I M / M Q R G N F R N Q R  
L V S A G I R K V L / F L D G I D K A Q D  
I L T E Q S D L V L / L S A E A K S V T E  
K R K E K D S K A F I L A T D W N D D D L  
H Y H D D D E L I L / P V K R K V V K K K  
R R K P L P P V G F / A G A M A E A R E K  
R E K G D L T F T F / P V V F M G E S D E  
S P A V V Q G M A Y / A A A M R G Q K Y S  
E G F G S T S H V H / W V Q E I S D S R P  
T K K P K R F P V L / L T A Q T S K D P E  
K A T P S A P T V M / A V V N P K E E L K  
K E E Q I P K D I F / P V T E T V D G Q G  
G P S Y Q Q G L A M / A A A F S G Q T V K  
R S T P P R S S L Y I P A L T P S L G A K  
V A D S T T S Q A F / P L R A G G N G Q L  
R R H R E M S K L L / A T V V S G Q K Q D  
G P M G Q P L Q V L / T L N I E D E H R L  
K D R I S V V Q A L / V L T Q Q Y H Q L K  
T P K T V G T S C Y / H C G T A I G C N C  
A S A P P P P Y V G / S G L Y P S L A G V  
A S T G P P V V A M / P V V I K T E G P A  
L T D Q G I A A A M / S S A I Q P L I M A  
M S S A I Q P L I M / A V V N R E R D G Q  
W P G P E P P A V S / L A M T M E H K D R  





































MA/CA A P F S G R G G N Y / P V Q Q I G G N Y T  43 
CA/P2 G G P G Q K A R L M / A E A L K E A L A P  43 
PVNC L A P A P I P F A A / A Q Q K G P R K P I  43 
NC/Pl M A K C P N R Q A G / F L G L G P W G K K  43 
amino acids were common  in  the P3 position  (not  shown). in  Gag  is always  a type 1 site while the processing site at  the 
The  argument for the  existence of two classes of sites  is carboxyl terminus of the  capsid  protein is usually a type 2 site 
strengthened by the  observation  that  the classes of sites were, and never  a type 1 site  (Table I). This  conservation of proc- 
to  a degree,  conserved in  their genomic  location. The process- essing site type and location is evident in all 10 retroviral 
ing site located at  the  amino  terminus of the capsid protein genomes examined. 
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TABLE I1
Number of each  amino acid found in positions PI0 through PIO' for all 46 protease cleavage sites 
P10 P9 P8 P7 P6 P5  P4  P3  P2 PI P1' P2' P3' P4' P5' P6' P7' P8' P9' P10' 
CYS 1 1 3 1 




2 3 2 1 3 5 2 3  
T h r 2 4 5 3 3 4   6 2  
3 
2 
Pro 4 9 6 8 6 9 1 2 1  
1 3 4 3 2 1 2 3 1 4  
A l a 6 4 2 3 2 2   5 4 1 1  1 
5 7 6 4 2 9 5  
G l y 6 4 2 7 5 1  
9 6 9 3 5 1 3 4 3 3  
3 2  1 3  2 3 2 4 9 4 9 2 4  
Asn 1 1 1  5 
ASP 2 2 1 5 2  1 1  
1 2 2 1 2 2 5 1  
G i u 1 3 4 3 3 1  
2 1 1 2 4 3 3 2  
1 2  1 2 4 2 6 4 1 1 3  
G i n 1 2 2 3 5 6  9 
His 1  1 2 
1 3 6 6 2 2 6 1 6 1  
1  1  1 1 1 2 
A r g 4 3 1 2 1 4   2 3  
2 2 3 1  
L y s 5 3 7 3 5 5   3 6  
3 2 3 1 4 2 3 4  
Met 2 
2 1 5 4 3 5 3 8  
2 1  1 3 1 7 1 1 3 3 2  
Ile 2 2 2 3  6 6 2 4 4 2  
1 1 1  
Leu  4  2 
1 1 1  
2 2   2 5   3 1 6  7 7 3 3 2  
V a l 1 3 1 3 2 2 2 2 1 3  
3 2 4 3  
Phe 2 2 2  10 2 2 1 
5 1 1 6 1 1 2 2 2 1 2  
Tyr 2 1 1 2 1 I 1  1 
1 






PI0 PS P I   P I '  PS' P I O '  
Poslt lon 
. .  
. .  
P I 0  P 5   P I  P I '  P5' PIO'  
. .  
Posltlon 
FIG. 1. Analysis of amino acid composition of retroviral 
protease processing sites. A ,  the  number of different  amino acid 
found at  each position from P10  through  P10'  in  the 46 retroviral 
protease cleavage sites  shown  in  Table I. B,  sum of the  hydropathy 
index (39) of the  amino acids found  in  each position is plotted for the 
46 retroviral  processing sites. In this  analysis,  the  sum of the  hydro- 
pathic index is calculated for each position  by multiplying  the  number 
of each amino acid by its  hydropathic value  before summation  to give 
a weighted value  based on the frequency of appearance. 
The sequence patterns associated with the type 1 and 2 
sites located at the  boundaries of the  capsid  protein  are  not 
different from other  type 1 and 2 sites located  elsewhere in 
the genome. One possible  exception is the  type 2 sites located 
at the carboxyl terminus of the capsid protein which fre- 
quently  contain a basic amino acid in  the P3 position. In  type 
2 sites located elsewhere in  the genome, the  P3 position is 
generally occupied by hydrophobic or uncharged  polar  amino 
acids. 
Zdentification of PR Cleavage Sites by Sequence  Searching- 
We were interested  in developing computer  methods  to  predict 
potential processing sites  within  Gag  and  Pol, based on  the 
sequences  flanking  the 46 known  processing sites. To preserve 
the relative importance of each  amino acid a t  each position, 
the sequences  from positions  P4  to  P3' were aligned  relative 
to  the scissile bond  and a  weight matrix was constructed from 
the  number of occurrences of each  amino acid at each position 
(29, 30). The ANALYSEP program performs searches for 
those sequences which exceed a specified score when com- 
pared  to  such a  weight matrix  (30).  We began by using this 
program  to identify potential processing sites  in a database 
consisting of the Gag, Pol,  and  PR  amino acid  sequences of 
all 10 retroviruses. When  the weight matrix was derived  from 
all 46 P R  cleavage sites, 7 of the  top 10 and 12 of the  top 20 
scores corresponded to known  processing sites (Fig. 2 A ) .  
Approximately half of the known  processing sites  in  the Gag, 
Pol,  and P R  sequences of the 10 viruses were identified before 
the  search efficiency began to decrease. When  searches were 
performed  using a  weight matrix derived  from  only the  type 
1 sites (16 sites) or only  type 2 sites (21 sites), 8 of the  top 10 
scores  corresponded  to known cleavage site sequences. (Fig. 
2, panels €3 and C). The processing sites identified in Gag  for 
the 10 retroviral genomes are  shown  in Fig. 3A. Only those 
scores which fell within  the efficient portion of the search 
(the region of the diagonal line  in Fig. 2, B and C) are included. 
None of the  nine known  cleavage sites  that were not classified 
as  type 1 or 2 were identified. However, 25 of the 33 type 1 
and 2 sites were identified, as were three sequences not 
representing known  processing sites.  The efficiency of cleav- 
age site recognition in  Pol was much  less than for  Gag (data 
not  shown). 
The success of the  searches a t  identifying known  processing 
sites  with a fair degree of reliability  encouraged us to search 
five additional  retroviral genomes, in which  processing sites 
have  not  been  experimentally identified,  for potential  proc- 
essing  site sequences in Gag. The  retroviral genomes exam- 
ined were diverse consisting of three lentiviruses, a foamy 
retrovirus,  and  an oncovirus. The searches, conducted with 
data bases derived from either type 1 or 2 cleavage site 
sequences, identified processing site sequences of equal or 
better quality than many of the known cleavage site se- 
quences. Many of the type 1 cleavage site sequences are 
located in genomic positions where protease cleavage sites 
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TABLE I11 
Number of each  amino acid found  in  positions  PI0  through P10’ (type  1  sites) 
P10  P9 P8 P7 P6 P5 P4 P3 P2 P1 P1’  P2’ 3’ P4’ P5’ P6’ P7’ P8’ P9’  P10’ 
CY s 1 1 
Ser 2 2 3   4 1  1 1  2 1 1 
T h r  1 2  3 3 3  2 1 1 1 1 1  3 
P r o 1 3 1 3 3 4 3  16 1 3 1   4 1  
Ala 4 1 1 1  1 3  1 1 1 1  1 2 1 1  
Gly 2 1 3 2  1 1  1 5 3 7  1 
Asn 1 4 1 2 1 3  
Glu 2 3  1 1 1 1  2 1 1 2  1 
Gln 1 2 2 1 1  6 2 4  3 3 
His 1 1 1 2 2 1 1  
Arg 2 1 2 1 2 1 1 2  
Lys 2 1 1 1 1 2  1 3 1   1 3  
Met 1 1 2  1 1 
Ile 1 1  3 6 1 2 2 1  
Leu 1 1 2 1 3   2 2  1 1 1 1  
Val 1 2 1 1 1 1  6 3   1 2 1 1  1 
Phe  1 1 1  7 1 
Tyr  2 1 1 5 1 
Tn, 1 
ASP 1 1 1 3 1  1 1 2 1 
TABLE IV 
Number of each  amino acid found  in  position  PI0  through PlO‘ (type 2 sites) 
P10 P9 P8  P7 P6 P5 P4 P3 P2 P1 P1’ P2‘ P3’ P4‘ P5’ P6’  P7‘ P8’ P9’  P10’ 
c y s  1 
Ser 1 2 3 2 1 2  1 2 1   3 1 2 1  2 
T h r  1 2 3 1 2 1   2 3 1 1   1 3 1 1  
P r o 3 4 5 4 1 3 8 1   4 3 3 3 2 5 3  
A l a 1 2 1 2 1 1 2 2 5   1 9 5 7 2 2 1 2   2 1  
Gly 3 3 1 2 1   2 1 1  1 1 2 3   1 1 2  
Asn 1 2 1 1 1  
Glu 1 1 3 2 1  1 2 1 5 1 1 1 2  
Gln 3 5  1 2 3 2 1 2 3 1 1 1  
His 1 1 1 2 1  
A r g 2 3 1 1 1 2  2 1 3 1 3 1 1 1  
L y s 3 1 4 3 4 4 1 4   1 1 2 3 2 4  4 
Met 1 1 3 1  4 1 3 1  1 
Ile 2 1 1  2 1 1 1  
Leu 1 2 1 1 3 2 1 0 7 2   1 2  1 3 1  
Val 3 1 1 1 1 8  5 4 3 1  1 1 1  
Phe  1 1  3 1 
TYr 1 1  1 1 1 
Trp 3 1 
ASP 1 2 1 1  1 1  1 3 2 1  
would be expected  to  occur (Fig. 3B) .  Searches  for  type 2 sites 
identified very few sequences  when  performed  under  the  same 
stringent  conditions  as  the  type 1 sites.  These  results suggest 
known processing site  sequences  can be used  with  some  suc- 
cess  to identify likely processing sites  in  proteins,  particularly 
type 1 sites. 
Test of P1 Specificity: Mutagenesis of the PI Amino Acid in 
a Pol Cleavage Site-Analysis of the  amino  acids  at  the P1 
position of retroviral  processing  sites  indicated hydrophobic 
amino acid were preferred,  with Leu, Phe,  Tyr,  and  Met being 
the most common  (Table 11). Curiously,  while  Leu appeared 
over 30% of the  time,  the  similar  amino  acids Val and Ile did 
not appear at all (Table 11). A consideration of side-chain 
structure of the excluded amino  acids  indicated  that  the  amino 
acids  in  the P1 position  have  the  common  feature of being 
both  uncharged  and  unbranched  at  the  P-carbon. 
To test the significance of this observation, amino acid 
substitutions were introduced by site-directed mutagenesis 
into  the P1 position of a type 1 processing site  (SFNF/PQI) 
located at  the  amino  terminus of the  PR-encoding  domain  in 
the  HIV-1 pol gene. This  site,  as well as  the  other  sites  in  Pol, 
is cleaved  by the  PR when  the  entire  pol gene is expressed in 
bacteria (32, 33, 40). The  Phe codon for  the P1 amino acid 
was  mutagenized to encode  14 other  amino acids. The  mutated 
pol genes were expressed  in E. coli under  control of the lac 
promoter  and  the  extent of processing determined by Western 
blot  analysis (Fig. 4A). In  this  assay,  the  appearance of mature 
forms of the  viral reverse transcriptase (64 and 51 kDa) is 
indicative of proper P R  activity, while the size of the processed 
P R  (normally 11 kDa)  indicates  whether processing has oc- 
curred at  the  mutated processing site.  Three  distinct  pheno- 
types were observed depending  on  the  amino acid substituted 
into  the P1 position.  Substitution of Leu  for Phe  permitted 
cleavage to occur at  the  mutated  site  at  near wild-type levels 
as  indicated by the  intensity of t he   PR   p l l  band (Fig. 4B). 
An intermediate  phenotype,  characterized by reduced 
amounts of mature p l l ,  was observed  when Ser  and Gly were 
substituted at   the  P1 position. The  Ser  substitution  appar- 
ently reduces the  amount of mature p l l  more than  the Gly 
substitution. The remainder of the  mutations  tested  had a 
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FIG. 2. Identification of processing site sequences using pat- 
tern searches. Each identified sequence is assigned a quality score 
relating to  the degree of similarity to a weight matrix derived from 
the processing site sequences in  Table I (29). In  this plot the number 
of correctly identified processing sites is plotted versus the total 
number of sites identified. A line with a slope of one indicates the 
identification of only known processing sites. A slope greater than 
one indicates the additional identification of other related sites. The 
point where the line turns in  a vertical direction indicates the position 
where most of the identified sequences are not known processing 
sites. Searches were performed using processing site sequences from 
positions P4 through P3’  to define the motif. Searches used all 46 
processing site sequences (panel  A ) ,  the 16 type 1 sites (panel  B ) ,  or 
the 21 type 2 sites (panel  C )  to define the weight matrix. 
Associated with the intermediate and negative phenotypes 
for processing at  the mutated  site were the presence of several 
larger products (the most abundant being 25,  29, 17, and 15 
kDa) that were detectable with anti-PR antibody by Western 
blot (Fig. 4B). The larger products were present with all 
amino acid substitutions  tested except Leu but were absent 
when the pol gene contained  a  mutation (D25I) that elimi- 
nates protease activity (data not shown), suggesting they 
result from protease activity. Several of the larger protein 
products can be predicted from the organization of the pol 
gene. The 25-kDa species was probably formed by cleavage at 
the carboxyl terminus of PR, resulting in the retention of the 
amino-terminal polypeptide that is normally cleaved from the 
PR.  Substitutions negative or reduced for processing at  the 
amino  terminus of PR also exhibited reduced processing at 
the other  sites in Pol (Fig. 5). The amount of processing at 
the distal sites appeared to correlate with the amount of 
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FIG. 3. Searches of known and unknown protease process- 
ing  sites in 15 retroviral Gag protein sequences. A ,  the positions 
and type of processing sites in Gag for the 10 retrovirus genomes 
examined in which processing sites  are known. Gag, represented by 
the long open  box, is aligned by the cleavage site that produces the 
amino terminus of the major capsid protein (CA).  The thick black 
boxes indicate the positions of the zinc finger motif found in the NC 
protein. The  total number of amino acids in Gag is indicated at right. 
Type 1 sites, indicated by the bold vertical  lines, have proline in the 
P1’ position. Type 2 sites, which contain either Ala, Leu, or Val in 
the P1’ position, are indicated by the th in  vertical lines. A small 
number of processing sites  contain  amino acids other than Pro, Ala, 
Leu, or Val at the P1’ position and are designated by the dotted 
vertical lines. The arrows indicate protein sequences identified as 
potential PR cleavage sites  in  a search using either type 1 sites (bold 
arrows) or type 2 sites (thin arrows) to derive the weight matrix. 
These  sites have quality scores values that fell within the diagonal 
range of the plots shown in Fig. 2, B and C. B, location and type of 
possible processing site sequences in Gag for retrovirus genomes in 
which processing sites have not been characterized. Arrows denote 
possible type 1 and 2 processing site sequences of equal of greater 
quality to those sequence identified as described for panel A. 
mature reverse transcriptase  p51  and p64  were present with 
all mutations tested, many extra bands were also evident. 
These  bands were also present when the pol gene contained  a 
mutation (D25I) that eliminated protease activity (PR-), sug- 
gesting they  result from E.  coli proteinase activity on the Pol 
precursor. These  results show that substitutions that blocked 
processing at  the mutated  site reduced but did not eliminate 
protease activity. 
DISCUSSION 
To understand the sequence requirements that define spec- 
ificity of the retroviral protease, we compared the sequences 
of cleavage sites from a number of retroviruses. Retroviral 
proteases recognize a heterogeneous collection of sequences 
as cleavage sites. Despite the heterogeneity, definite patterns 
of amino acid preference were found. Several schemes have 
been previously described to account for PR specificity (41- 
43). While the general features of those schemes are  apparent 
in the  patterns described here, the larger number of sites used 
here has allowed  more detail to be added and has revealed the 
existence of two families of cleavage sites that are, in part, 
conserved in location in all retroviral genomes. 
Because we selected sites from distantly related retrovi- 
ruses, sequence specificity evolving within a family of closely 
related retroviruses would  be  overlooked in this classification 
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FIG. 4. A.  map of PART-2 PO/ expression plasmid. Amino acid 
suhstitntions generated at the 1’1 Phe codon of the processing site 
located at the  amino  terminus of t  he PK domain are indicated. PART:! 
contains the HIV-I  pol open reading frame under transcriptional 
control of the lnc promoter. The plasmid also contains  an  fl phage 
replication origin ( / I  I(;). The sequence of the t.ype 1 processing  site 
located at the  amino  terminus  of  the 1’11 domain is shown for positions 
1’4 to P3’. Suhstitution mutations for the 1’1 amino acid ([’he) are 
also shown. 13, Western blot of HIV-I  Pol expressed in k,’. coli: 
])rocensingtoprotease. Stationar~phasecultrtresof.JM101 containing 
],ART2 (32) or pART2  with a mutation in the  codon  of  the PI amino 
acid of the  processing  site located at  the  amino  terminus of the P I <  
domain were induced for expression  of pol hv the  addition  of isopro- 
I)yl-4-n-thiogalactopvranoside. Cells were pelleted, Ivsed, suhjerted 
t o  sodium dodecyl sulfate-polvacrvlamide gel electrophoresis, trans- 
ferred onto nitrocellulose, and exposed to anti-1’R polvclonal anti- 
I)ody (33). The nrrows denote  the  position  of properly processed HIV- 








FIG. 5. Western blot of HIV-1 Pol expressed in E. coli: 
processing  to  reverse  transcriptase. The Western hlot WAS per- 
hrmed as descrild in Fig. 4 except anti-RT monoclonal antihodv 
was used. The nrrotrw indicate  the  position  of  RT p64 and p51. ( I ’ I I ” )  
indicates  the pol gene  contained a mutation (11251) that renders the 
protease  inactive (:I:{). 
of processing site sequences. An example of such  a  phenom- 
enon may he the  presence of Asn at  P2 in type  1  sites, which 
appears  to he restricted  to  primate  lentiviruses  (Tahle 111). In 
this regard, Henderson et al. (43) examined  the cleavage sites 
in  a  number of closely related  primate  lentiviruses  and pro- 
posed the  existence of three  classes of cleavage sites. In their 
analysis,  class 1 sites  correspond  to  the  type 1 sites descrihed 
here, class 2 sites  share  a P4 Arg, a  P1’  Phe,  and  a P2’ Leu, 
while the  class 3 sites  share  a P2’ Clu or Gln.  The  class 2 and 
3 sites roughly correspond  to  the  type 2 sites descrihed in this 
broader  sampling of processing sites. 
The  discernahle  patterns of sequence preference from po- 
sitions P4 through PB’ flanking the scissile hond correlate 
with the size of the recognition sequences of the retroviral 
proteases. Several lines of evidence suggest that  the size of 
the PR recognition sequence is small.  Kotler ct al. (24) have 
shown that  peptides with five, hut  not  three,  amino acids on 
each  side of the scissile  hond are cleaved hv the  avian mye- 
loblastosis virus PR, and peptides as short as seven amino 
acids  are cleaved hy the  HIV-1 PR without significant loss of 
efficiency (26-28). Crystallographic  structure  determinations 
of the  HIV-1 PR with a  hound  inhihitor suggest f o r  7 residues 
of the  suhstrate may reside in the hinding cleft (20-22). In 
addition, we were able to delete virus-specific sequences to 
wit,hin four amino  acids of the  HIV-1 cleavage site  upstream 
of the PR and still observe processing at  that  site (32). Thus, 
the  amino  acids between P4 and P.7’ mav represent all of the 
sequence  information needed to  permit  appropriate cleavage 
at   the scissile hond. 
Tu)o Types of Clcaoage Sitcs Arc Ilctcrmincd by thr PI’ 
Amino Acid-Evidence supporting  the concept of two distinct 
classes of cleavage site  sequences was based primarilv on two 
ohservations. First, in sites where the amino acid in 1’1’ is 
Pro (type 1 sites), we found distinct  differences in the  flanking 
amino acid  sequence compared  to sequences in which the P I  ’ 
position was occupied by Ala, IRU, or Val  (t.ype 2 sites)  (Tahles 
111 and IV). Second, certain classes of cleavage sites are 
preferred at certain locations in all retroviral genomes. For 
example,  the cleavage site sequence that  generates  the  amino 
terminus of the major  capsid protein is alwnvs a  type 1 site. 
In contrast, the cleavage site that generates the carhoxvl 
terminus of the major  capsid protein is nearlv alwnvs a type 
2 site  and never a  type  1  site  (Tahle I, Fig. :M ). 
There  are several  possihle reasons whv two t-ypes of cleavage 
sites might exist. Because of the high conservation of the 
cleavage sites  around  the major capsid  protein, it is possible 
that these sites are functionallv different. For HIV-I it has 
been shown that the Gag precursor undergoes an ordered 
series of cleavage events (44, 45) that correlates with the 
different  rates of cleavage at   the different processing sites (27, 
46, 47). The  rate of cleavage  may he influenced not only hv 
the  amino acid composition of the cleavage site  hut also hv 
the  structural cont.ext and  surface accessihilitv of the process- 
ing  site. However, it is not possihle at  this  time  to  determine 
the role secondary  structure or accessihilitv mav plav in 
protease cleavage site  sequence  selection. 
Degenrracy within PN Cl~auagr Sifcs-The patterns oh- 
served in amino acid preference were less apparent when 
examining  the  sites individually. Onlv about 50r; of the type 
1 or 2 cleavage site  sequences listed in Table I had flanking 
amino  acids from positions P4 to P.7’ that were in complete 
agreement with the two  general patterns for t.ype 1 or 2 
cleavage sites. The majoritv of the remainder o f  the sites 
differed by a single amino acid. A few sites even appeared  to 
contain  elements of both cleavage site families, for example 
the  HIV-1 NC/p6 sit.e has  Phe-Leu in the P - P I ’  positions, 
and  the MuI,V p12E/p2E site  has Val in P1’ and Gln in 1’3. 
With  the exception of the cleavage sites  flanking  the major 
capsid  protein,  none of the  other cleavage sites in Gag or I ’ d  
were  conserved  with respect to having a t?rpe 1 or 2 site at a 
specific location. I t  is possible that processing sites at other 
locations may not have the same structural and sequence 
constraints as the cleavage sites flanking the major cnpsid 
protein. 
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Structural  Requirements of the PI Amino Acid-Of the 46 
processing sites considered, eight different amino acids ap- 
peared in the P1 position (Table 11). However, Phe,  Tyr, Leu, 
and Met accounted for nearly 90% of the sites, suggesting 
these amino acids best fit the sequence requirements of the 
P1 amino acid. Thus,  the specificity of the amino acid side 
chain in the P1 position is  best described as large, hydropho- 
bic, and unbranched at the /?-carbon. The absence of the 
hydrophobic amino acids Ile and Val from the P1 position of 
cleavage sites suggested that  the structure of the P1 amino 
acid side-chain at  the /?-carbon is an important  determinant 
of cleavage site specificity. 
There  are several possible reasons why an amino acid with 
a branched @-carbon may  be excluded from the P1 position. 
First, a branched amino acid may make hydrolysis of the 
peptide bond difficult, as is seen with some peptide bonds. An 
example is the peptide bond following the amino acids Val 
and Ile,  which are  particularity  resistant to cleavage  by acid 
hydrolysis (48). While it is generally agreed that aspartic 
proteinases hydrolyze peptide bonds by general base catalysis 
(49), there may  be similar constraints by the upstream  amino 
acid side-chains in both mechanisms of hydrolysis. Second, it 
is possible a  @-branched side-chain on the P1 amino acid may 
not allow proper association of the substrate with the S1- 
binding pocket of the PR.  Third, an unbranched amino acid 
may be required for some structural  feature of the processing 
site. One possible structural constraint could involve the 
assumption of the cis conformation by prolines in  the P1' 
position. By  analogy with retroviral PR cleavage sites, 50% 
of the prolines known to be in a cis conformation within 
proteins  are preceded by the amino acids Phe,  Tyr, and Leu, 
and only 3% are preceded by the branched  @-carbon amino 
acids Ile, Val, and Thr (50). 
Mutational analysis of the P1 position confirmed the se- 
quence requirements of the P1 amino acid in a  Pol cleavage 
site. Replacement with the @-branched amino acids Val, Ile, 
Pro, and Thr blocked processing at the mutated site and 
reduced the amount of processing at  the other  sites  in  Pol 
(Figs. 4B and 5). This is in agreement with an observation 
made by Kotler et al. (24) in which substitution of Ile in  the 
P1 position of an avian myeloblastosis virus PR peptide 
substrate eliminated cleavage and  the peptide functioned as 
an inhibitor. It is  not known if the reduction of cleavage at 
the other processing sites in pol seen with some mutations is 
the result of inhibition of protease activity by the mutated 
sequence or by the retention of a peptide at  the amino ter- 
minus of protease. The ability of ser and Gly to substitute, 
at least in part, for Phe may  be related to  the fact that these 
amino acids are found in the P1 position at other processing 
sites, although never with Pro in P1' (Table I).  This result  is 
in agreement with those of Partin et al. (51), in which a  Ser 
substitution at  the P1 position of the type 1 site at  the amino 
terminus of PR  in a native protein  substrate allowed efficient 
processing in vitro by protease provided both in cis and  in 
trans. However, a  Ser  substitution in the P1 position of the 
type 1 site located at  the amino  terminus of CA prevented 
cleavage at this site in vitro with both peptide and native 
protein  substrates (51). 
Of the amino acid substitutions we tested at  the P1 position, 
only Leu permitted cleavage at or near wild-type levels. This 
suggests Leu  may function as an equivalent replacement for 
Phe without a significant effect on cleavage. The examination 
of amino acid sequences from different HIV-1 isolates (52) 
also suggests  Leu and Cys  may  be able to serve as functional 
equivalents for Phe in the P1 position of the processing site 
located at  the amino terminus of PR. While Phe is found 
most often in the P1 position of this processing site  in the 
different isolates, two isolates have Leu (HIVOYI and 
HIVHAN) and one isolate has Cys (HIVSF2) at the P1 
position. 
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